4 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
14 May 24
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
8:03am
) meeting: Takeda presented seven poster presentations, which were originally presented at the 2023 American Epilepsy Society meeting. These posters
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
8 Mar 24
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8:20am
at the American Epilepsy Society 2023 annual meeting. This preclinical data demonstrates that OV329 elicits an electroencephalogram response which
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
12 Nov 20
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:28pm
of the world.
Presented three abstracts from the OV101 Angelman syndrome clinical development program at the Child Neurology Society/International Child … X syndrome clinical development program at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) 2020 Virtual Congress
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
11 Mar 19
Regulation FD Disclosure
2:51pm
Nishi, T et al. Inhibition of Cholesterol 24-hyrdroxylase Improves the Survival of a Mouse Model… Society for Neuroscience, poster, Nov 2018 2 Hasegawa … S, et al. Cholesterol 24-hydroxylase Inhibition is a Novel Pharmacological Mechanism That Exerts Neuroprotective Effects… Society for Neuroscience
- Prev
- 1
- Next